Indivior Knew Suboxone Film Did Not Have Greater Child Safety Than Tablet, Grand Jury Claims
Indictment alleges Indivior falsely cited concerns about pediatric exposure to tablets in discontinuing the formulation; FDA official says company tried to mislead agency and bar competition for Suboxone.
You may also be interested in...
Submission of manipulated clinical data to support product approval is a ‘major concern’ for the DoJ, consumer protection branch director Gusav Eyler says, adding that some of the problems relate to outsourcing of trials. Also, DoJ and HHS OIG are using data analytics to identify outliers in prescribing and reimbursement claims.
Indivior is working on receiving ex-US approvals for its opioid abuse treatment products and building its cash reserves but faces future uncertainty over US generic competition and a US Department of Justice legal action.
Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.